The Functional Dyspepsia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Functional Dyspepsia pipeline products will significantly revolutionize the Functional Dyspepsia market dynamics.
DelveInsight’s “Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Functional Dyspepsia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Functional Dyspepsia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Functional Dyspepsia Market Insights
Some of the key facts of the Functional Dyspepsia Market Report:
-
The Functional Dyspepsia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
Antiemetics accounted for approximately 20% of the therapeutic market in the United States in 2023.
-
At present, the only drug specifically approved for functional dyspepsia is ACOFIDE (Acotiamide), developed by Astellas Pharma and Zeria Pharmaceuticals, with approval limited to Japan.
-
The main goal in managing functional dyspepsia is to alleviate symptoms, as the condition often shows a pattern of relapses and remissions. Treatment options consist of proton pump inhibitors, H2-receptor antagonists, prokinetic agents, and antidepressants. Additionally, testing for and treating Helicobacter pylori is advised when relevant.
-
According to a research article published in April 2021, acotiamide immediate release 300 mg once daily was found to have similar efficacy and safety as acotiamide immediate release 100 mg three times daily. Throughout the course of a four-week therapy session, patients with FD-PDS showed a significant improvement in QoL.
-
Large corporations are creating possible pharmacological candidates to enhance the Functional Dyspepsia therapy situation, including Zeria, Renexxion, and others.
-
In a Korean, a study completed the Rome III questionnaire where, 7.7% had dyspepsia; postprandial distress was reported by 5.6% and EPS by 4.2%, while 27% had both PDS and EPS
-
According to AC et al., 2020, approximately 80% of individuals with dyspepsia have no structural explanation for their symptoms and have functional dyspepsia. Functional dyspepsia affects up to 16% of otherwise healthy individuals in the general population
-
Key Functional Dyspepsia Companies: GlaxoSmithKline, Dexa Medica Group, Astellas Pharma, Zeria Pharmaceutical, Korea United Pharma, Daewoong Pharmaceutical, Eisai Co., Ltd., Johnson & Johnson, Dong-A ST Co., Ltd., Astellas Pharma Inc, Materia Medica Holding, Forest Laboratories, and others
-
Key Functional Dyspepsia Therapies: GW679769 oral tablets, DLBS2411, YM443, Acotiamide hydrochloride hydrate, UI05MSP015CT, DWJ1252, Rabeprazole, Imonogas, Z-338, Motilitone ®, YM443, Kolofort, Itopride Hydrochloride, and others
-
The Functional Dyspepsia epidemiology based on gender analyzed that Functional Dyspepsia affects females more than males
Functional Dyspepsia Overview
Functional dyspepsia is a common gastrointestinal disorder characterized by persistent or recurrent symptoms of upper abdominal discomfort, bloating, early satiety, and nausea, without any identifiable structural or biochemical abnormalities. It is often classified into two subtypes: epigastric pain syndrome, which involves pain or discomfort in the upper abdomen, and postprandial distress syndrome, characterized by discomfort after meals. The exact cause of functional dyspepsia is not well understood, but it may involve factors such as impaired gastric motility, increased sensitivity of the stomach, and psychological factors. Treatment typically focuses on symptom relief through lifestyle changes, dietary modifications, and medications.
Get a Free sample for the Functional Dyspepsia Market Report -
https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights
Functional Dyspepsia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Functional Dyspepsia Epidemiology Segmentation:
The Functional Dyspepsia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Functional Dyspepsia
-
Prevalent Cases of Functional Dyspepsia by severity
-
Gender-specific Prevalence of Functional Dyspepsia
-
Diagnosed Cases of Episodic and Chronic Functional Dyspepsia
Download the report to understand which factors are driving Functional Dyspepsia epidemiology trends @ Functional Dyspepsia Epidemiological Insights
Functional Dyspepsia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Functional Dyspepsia market or expected to get launched during the study period. The analysis covers Functional Dyspepsia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Functional Dyspepsia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Functional Dyspepsia Therapies and Key Companies
-
GW679769 oral tablets: GlaxoSmithKline
-
DLBS2411: Dexa Medica Group
-
YM443: Astellas Pharma
-
Acotiamide hydrochloride hydrate: Zeria Pharmaceutical
-
UI05MSP015CT: Korea United Pharma
-
DWJ1252: Daewoong Pharmaceutical
-
Rabeprazole: Eisai Co., Ltd.
-
Imonogas: Johnson & Johnson
-
Z-338: Zeria Pharmaceutical
-
Motilitone ®: Dong-A ST Co., Ltd.
-
YM443: Astellas Pharma Inc
-
Kolofort: Materia Medica Holding
-
Itopride Hydrochloride: Forest Laboratories
Scope of the Functional Dyspepsia Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Functional Dyspepsia Companies: GlaxoSmithKline, Dexa Medica Group, Astellas Pharma, Zeria Pharmaceutical, Korea United Pharma, Daewoong Pharmaceutical, Eisai Co., Ltd., Johnson & Johnson, Dong-A ST Co., Ltd., Astellas Pharma Inc, Materia Medica Holding, Forest Laboratories, and others
-
Key Functional Dyspepsia Therapies: GW679769 oral tablets, DLBS2411, YM443, Acotiamide hydrochloride hydrate, UI05MSP015CT, DWJ1252, Rabeprazole, Imonogas, Z-338, Motilitone ®, YM443, Kolofort, Itopride Hydrochloride, and others
-
Functional Dyspepsia Therapeutic Assessment: Functional Dyspepsia current marketed and Functional Dyspepsia emerging therapies
-
Functional Dyspepsia Market Dynamics: Functional Dyspepsia market drivers and Functional Dyspepsia market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Functional Dyspepsia Unmet Needs, KOL’s views, Analyst’s views, Functional Dyspepsia Market Access and Reimbursement
Discover more about therapies set to grab major Functional Dyspepsia market share @ Functional Dyspepsia Treatment Landscape
Table of Contents
1. Functional Dyspepsia Market Report Introduction
2. Executive Summary for Functional Dyspepsia
3. SWOT analysis of Functional Dyspepsia
4. Functional Dyspepsia Patient Share (%) Overview at a Glance
5. Functional Dyspepsia Market Overview at a Glance
6. Functional Dyspepsia Disease Background and Overview
7. Functional Dyspepsia Epidemiology and Patient Population
8. Country-Specific Patient Population of Functional Dyspepsia
9. Functional Dyspepsia Current Treatment and Medical Practices
10. Functional Dyspepsia Unmet Needs
11. Functional Dyspepsia Emerging Therapies
12. Functional Dyspepsia Market Outlook
13. Country-Wise Functional Dyspepsia Market Analysis (2020–2034)
14. Functional Dyspepsia Market Access and Reimbursement of Therapies
15. Functional Dyspepsia Market Drivers
16. Functional Dyspepsia Market Barriers
17. Functional Dyspepsia Appendix
18. Functional Dyspepsia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Guarav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
